作为治疗神经母细胞瘤的途径,碳酸胺酶IX抑制是一种途径
Agne Petrosiute1, Audrius Zakšauskas1, Asta Lučiūnaitė2
1Department of Biothermodynamics and Drug Design, Institute of Biotechnology, Life Sciences Center, Vilnius University, Vilnius, Lithuania.
British journal of pharmacology
|January 8, 2025
概括
一种新型的碳酸酶IX (CA IX) 抑制剂通过减少瘤生长和化学激素分泌,对神经母细胞瘤治疗具有前景. 与CCR2抑制剂的联合治疗在临床前模型中进一步提高了疗效.
科学领域:
- 在瘤学瘤学.
- 生物化学 生化学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤缺氧是神经母细胞瘤 (NBL) 治疗的一个重要障碍.
- 神经母细胞瘤细胞依赖碳酸无水酶IX (CA IX) 在低氧条件下生存.
研究的目的:
- 设计和合成一种新的CA IX高亲和度抑制剂.
- 在临床前神经母细胞瘤模型中评估这种抑制剂的疗效.
主要方法:
- 合成一种具有高度亲和力和选择性的新型CA IX抑制剂.
- 在体外评估抑制剂对神经母细胞瘤细胞生长和球形形成的影响.
- 使用老鼠异种移植模型进行体内评估.
- 用CCR2抑制剂进行组合治疗.
主要成果:
- 该CA IX抑制剂有效降低了SK-N-AS细胞中缺氧诱导的酸化和球状细胞的生长.
- 抑制剂治疗减少了前瘤化学激素分泌 (IL-8,CCL2).
- 与CCR2抑制剂的联合治疗显著降低了小鼠瘤的生长.
- 联合治疗导致了适应性耐药性,由增加的VEGFR水平表明.
结论:
- 碳酸无水酶IX在神经母细胞瘤的进展中起着关键作用.
- 一种新型的CA IX抑制剂证明了神经母细胞瘤的治疗潜力.
- 涉及CA IX抑制的组合疗法为神经母细胞瘤治疗提供了一个有前途的策略.
更多相关视频
08:43Rat Model of Blood-brain Barrier Disruption to Allow Targeted Neurovascular Therapeutics
Published on: November 30, 2012
20.2K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
